Blood CancerArchives
Emerging strategies in CAR-T cell therapy for acute myeloid leukemia: overcoming heterogeneity and improving safety through dual-antigen targeting
Blood Cancer 10 min.
Acute myeloid leukemia (AML) is a highly aggressive and heterogeneous hematological malignancy of the bone marrow that has an annual incidence of 4.3 per 100,000 in the United States, increasing with age [1]. Accounting for about 80% of cases, AML is the most frequent type of acute leukemia in adults...
Genetic insights into acute lymphoblastic leukemia: the role of MDR1 and IL18 polymorphisms in Egyptian children
Blood Cancer 6 min.
Acute lymphoblastic leukemia (ALL) is a particularly aggressive form of hematopoietic cancer that is both physiologically diverse and clinically aggressive. The clonal proliferation and accumulation of immature lymphoid progenitor cells are the causes of this condition, which ultimately results in extensive...
B7-H3 nanobody-based CAR T cells control multiple myeloma growth, while dual BCMA/B7-H3 CAR T cells overcome antigen escape
Blood Cancer 7 min.
Multiple myeloma (MM) is a plasma cell malignancy characterized by the abnormal accumulation of plasma cells primarily in the bone marrow (BM) [1]. This hematological malignancy is still considered incurable, mainly due to cellular heterogeneity and the development of therapy resistance. Recent advances...
WTAP promotes the proliferation of multiple myeloma by regulating the hippo pathway through m6A modification of MAP6D1
Blood Cancer 1 min.
Multiple myeloma (MM) remains incurable, largely owing to the lack of effective therapeutic targets. Wilms' tumor 1-associated protein (WTAP) has been implicated in MM tumorigenesis, but its underlying molecular mechanisms remain unclear. This study aimed to elucidate the role of WTAP in MM progression....
Supporting treatment decision-making for patients with multiple myeloma post-DRd in Italy: a multi-criteria decision framework
Blood Cancer 6 min.
Multiple Myeloma (MM) is a rare hematological tumor affecting B lymphocytes and is the second-most commonly diagnosed hematological malignancy in Europe [1]. In Italy, MM accounts for 1.5% of all diagnosed tumors, with an annual incidence of approximately 5,700 cases [2] and a median age at diagnosis...
